Incannex Completes Dosing in Phase 1 Clinical Trial to Assess Multi-Use, Anti-Inflammatory Drug IHL-675A; Proceeds to Phase 2 Clinical Trials Oct 13, 2022 | ASX News, Incannex Healthcare (ASX:IHL)
